2-(4-Fluorophenyl)-2-(trifluoroacetamido)acetic acid | 1293367-30-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(4-Fluorophenyl)-2-(trifluoroacetamido)acetic acid
• 英文别名: 2-(4-fluorophenyl)-2-[(2,2,2-trifluoroacetyl)amino]acetic acid
• CAS: 1293367-30-2
• 化学式: C₁₀H₇F₄NO₃
• 分子量: 265.164
• InChiKey: GZWIWYAVWSSBJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-(4-Fluorophenyl)-2-(trifluoroacetamido)acetic acid 在 乙酸酐 作用下， 反应 2.0h， 生成 4-(4-fluorophenyl)-2-(trifluoromethyl)-4H-1,3-oxazol-5-one
  参考文献：
  名称：

  A Tandem [3+2] Cycloaddition-Elimination Cascade Reaction to Generate Pyrrolo-[3,4-c]pyrrole-1,3-diones

  摘要：

  An efficient tandem [3+2] cycloaddition-elimination cascade sequence has been developed enabling assembly of the pharmacologically relevant pyrrolo-[3,4-c]pyrrole-1,3-dione chemotype. The strategy involves simple mixing of readily accessible oxazolin-2-ones and pyrrole-2,5-diones in the presence of base under mild conditions, rendering the title compounds in typically excellent yields. Of note, this route allows for installation of three points of diversity and is ideal for combinatorial applications and parallel synthesis production campaigns.

  DOI：

  10.1055/s-0033-1338872
• 作为产物：
  描述：

  三氟乙酰氯 、 DL-4-氟苯甘氨酸 在 sodium hydroxide 作用下， 反应 3.0h， 生成 2-(4-Fluorophenyl)-2-(trifluoroacetamido)acetic acid
  参考文献：
  名称：

  A Tandem [3+2] Cycloaddition-Elimination Cascade Reaction to Generate Pyrrolo-[3,4-c]pyrrole-1,3-diones

  摘要：

  An efficient tandem [3+2] cycloaddition-elimination cascade sequence has been developed enabling assembly of the pharmacologically relevant pyrrolo-[3,4-c]pyrrole-1,3-dione chemotype. The strategy involves simple mixing of readily accessible oxazolin-2-ones and pyrrole-2,5-diones in the presence of base under mild conditions, rendering the title compounds in typically excellent yields. Of note, this route allows for installation of three points of diversity and is ideal for combinatorial applications and parallel synthesis production campaigns.

  DOI：

  10.1055/s-0033-1338872

文献信息

• Substituted pteridines for the treatment of inflammatory diseases
  申请人：Dollinger Horst

  公开号：US20060116370A1

  公开（公告）日：2006-06-01

  The invention relates to new pteridines which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.

  这项发明涉及新的蕨类素，适用于治疗呼吸道或消化系统的疾病或不适，关节、皮肤或眼睛的炎症性疾病，外周或中枢神经系统的疾病或癌症，以及含有这些化合物的药物组合物。
• Dihydrothienopyrimidines for the treatment of inflammatory Diseases
  申请人：POUZET Pascale

  公开号：US20120108534A1

  公开（公告）日：2012-05-03

  The invention relates to new dihydrothienopyrimidine of formula 1 , as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein X is SO or SO 2 , but preferably SO, and wherein R 1 , R 2 and R 3 have the meanings given in the description, and which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.

  本发明涉及一种新的二氢噻唑嘧啶化合物，其化学式为1，以及其药物学上可接受的盐、对映异构体、对映体、外消旋体、水合物或溶剂化物，其中X为SO或SO2，但优选为SO，R1、R2和R3在说明中给出了其含义，该化合物适用于治疗呼吸或胃肠道不适或疾病、关节、皮肤或眼睛的炎症性疾病、周围或中枢神经系统疾病或癌症，以及含有这些化合物的制药组合物。
• 6,7-Dihydrothieno[3,2-d]pyrimidine for the Treatment of Inflammatory Diseases
  申请人：POUZET Pascale

  公开号：US20140005154A1

  公开（公告）日：2014-01-02

  The invention relates to new dihydrothienopyrimidine of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein X is SO or SO 2 , but preferably SO, and wherein R 1 , R 2 and R 3 have the meanings given in the description, and which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.

  本发明涉及式1的新的二氢噻唑嘧啶，以及其药学上可接受的盐、对映异构体、对映体混合物、水合物或溶剂化物，其中X为SO或SO2，但优选为SO，R1、R2和R3具有所述描述中给出的含义，适用于治疗呼吸或消化不适或疾病、关节、皮肤或眼睛的炎症性疾病、外周或中枢神经系统疾病或癌症，以及含有这些化合物的制药组合物。
• COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR- ANTAGONISTS
  申请人：NICKOLAUS Peter

  公开号：US20140350035A1

  公开（公告）日：2014-11-27

  The present invention relates to new medicament combinations which contain in addition to one or more PDE4-inhibitors ( 1 ) at least one EP4 receptor antagonist ( 2 ), as well as the use thereof for the treatment of preferably respiratory complaints such as particularly COPD, chronic sinusitis and asthma. The invention relates in particular to those medicament combinations which contain, in addition to one or more, preferably one, PDE4 inhibitor of general formula 1 wherein X is SO or SO 2 , but preferably SO, and wherein R 1 , R 2 , R 3 and R 4 have the meanings given in claim 1, at least one EP4 receptor antagonist ( 2 ), the preparation thereof and the use thereof for the treatment of respiratory complaints.

  本发明涉及一种新的药物组合，除了一种或多种PDE4抑制剂（1）外，还包含至少一种EP4受体拮抗剂（2），以及其在治疗呼吸道疾病，如慢性阻塞性肺疾病、慢性鼻窦炎和哮喘等方面的应用。本发明特别涉及那些药物组合，除了一种或多种，首选一种通式1的PDE4抑制剂，其中X为SO或SO2，但优选为SO，R1、R2、R3和R4具有权利要求1中所给出的含义，还包含至少一种EP4受体拮抗剂（2），其制备和在治疗呼吸道疾病方面的应用。
• US7648988B2
  申请人：——

  公开号：US7648988B2

  公开（公告）日：2010-01-19